Background. Concerns have recently emerged about the efficacy and the quality of antibacterial generic products approved for use in humans.
Generic medicinal products are copies of patented drugs and can be marketed at low cost following patent expiration of the brand leader product. As with all pharmaceutical products, generic products must comply with standards of quality, efficacy, and reliability. The regulatory authorities of several countries, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and the World Health Organization (WHO) have issued guidelines presenting the terms and conditions under which generic medicinal products can be recognized as therapeutically equivalent to their brand name counterpart (reviewed in [1] ). Bioequivalence principles have been defined (ie, 20% acceptance range [80%-125%] for the 90% confidence interval of the ratio between test and reference least square means after log-transformation of the pharmacokinetic parameters of interest, maximum concentration (C max ) and area under the curve (AUC). The objectives of drug policies supporting the use of generic medicinal products are essentially economic: (1) to decrease the cost of medicines as part of healthcare spending, in particular in developed countries (eg, in France, it is estimated that €1.3 billion was saved by introducing such policy in 2008 [2] ), and (2) to facilitate access to care in developing countries (eg, expanded access to effective antiretroviral combinations for human immunodeficiency virus-infected patients). However, these economic considerations should not occur at the price of lower quality of patient care.
The therapeutic equivalence of generic medicinal products approved for use in humans has been challenged in various therapeutic areas, including neurology [3] , endocrinology, and cardiovascular diseases [4] . The question was also raised for antibacterial agents, especially following publication of a study performed with vancomycin generic products suggesting that, despite similar pharmacokinetic parameters and in vitro antibacterial activities, some vancomycin generic products were less bactericidal than the innovator in vivo in a neutropenic mouse thigh infection model [5] , and could induce more resistant subpopulations [6] . Following publication of these results, a debate started worldwide, involving the scientific communities, drug regulatory agencies, and the general public [7] . Questions were raised about the current assumptions from the WHO, FDA, and EMA, that 2 products of parenteral use are considered therapeutically equivalent if they are pharmaceutically equivalent. This issue is of concern, as (1) it would imply that patients may currently receive suboptimal antibacterial therapy depending on the product that they receive; and (2) deep changes would be required in the approval process of antibacterial generic products, including the need for more studies on efficacy, which would, in turn, translate into increased costs for approval. This systematic review of the literature was designed to objectively analyze published data regarding the efficacy and quality of antibacterial generic products.
METHODS

Search Strategy and Selection Criteria
We searched Medline and Embase for articles in English or French published any time before July 2013, using the following keywords in various combinations: generics, generic products, antibacterial, antibacterial agent, antibiotic, β-lactam agent, penicillin, cephalosporin, penem, fluoroquinolone, aminoglycoside, macrolide, cycline, glycopeptide, and vancomycin.
Data Extraction
Two independent researchers (P.T. and R.G.) reviewed all abstracts to identify articles that required full-text review, with a final decision reached through consensus. All articles were discussed with a third reviewer (A.-C.C.). For each reviewed article, we extracted data on the study setting, objectives, methods, and results, including details on the evaluated generic products. We systematically searched for additional articles in the reference lists of all articles reviewed. The heterogeneity of study designs and the limited number of articles available precluded any meta-analysis.
RESULTS
We identified 37 studies that met inclusion criteria: 15 focused on β-lactam agents (Table 1) , 10 on glycopeptides (Table 2) , and 12 on other antibacterial agents (Table 3 ). The majority of articles (73.0%) were published during the last 5 years (2008) (2009) (2010) (2011) (2012) . Study designs included analytical chemistry (measurement of active pharmaceutical ingredients and/or impurities, n = 9), in vitro susceptibility studies (eg, determination of minimal inhibitory concentrations [MICs] , minimal bactericidal concentrations [MBCs], time-kill curves, population analysis, n = 14), in vivo animal experiments (n = 6, including 5 studies using the neutropenic mouse thigh infection model), and clinical studies in humans (ie, pharmacokinetic studies, retrospective cohorts, studies on compliance and/or taste, quasi-experimental study, case report, n = 15). Studies originated from Asia (n = 9), South America (n = 8), Europe (n = 7), and North America (n = 6), or covered >1 continent (n = 7). Of the 37 studies, 14 (37.8%) suggested that some generic products may be inferior to the innovator in terms of purity (n = 2), in vitro activity (n = 3), in vivo efficacy in experimental models (n = 4), clinical efficacy (n = 2), taste (n = 2), or compliance and acceptability in children (n = 1).
Of the 15 studies on β-lactam generic products, 7 suggested that some approved generic products may be inferior to the innovator. Rodriguez et al found that, despite similar MICs and MBCs, the 9 generic products of oxacillin that they evaluated in the neutropenic mouse thigh Staphylococcus aureus infection model had lower E max (maximum effect in log 10 colonyforming units/g) than the innovator [8] . Jones et al evaluated 46 lots of piperacillin-tazobactam generic products manufactured in 17 countries and found that their in vitro activity, evaluated by incremental MIC antimicrobial assay, was on average 10% lower than that of the innovator [11, 12] . Lambert et al studied the pharmaceutical qualities of 34 generic products of ceftriaxone approved for use, and found that quality standards were violated on 18 occasions [15] . Subsequently, in a mathematical model based on Monte Carlo simulations, Schito et al suggested that most ceftriaxone generic products may not reach the required pharmacokinetic/pharmacodynamic parameters [16] . In a quasi-experimental study, Mastoraki et al found that the incidence of post-cardiac surgery infections was significantly increased in patients who received prophylaxis with a generic product of cefuroxime, as compared to the innovator [17] . Last, Cohen et al found that the acceptability and the compliance of amoxicillin-clavulanic acid generic products approved for oral Jones et al [11] , 2008 26 samples of piperacillintazobactam generic products from Philippines (n = 10 lots), India (n = 5), Greece (n = 3), China (n = 2), Spain (n = 2), Taiwan (n = 2), Portugal (n = 1), and Jordan (n = 1)
In vitro study (incremental MIC antimicrobial assay)
Compared to the innovator, all but 1 lot of generic product demonstrated significantly decreased activity, at −5 to −35% (average, −16%)
Data from this study were included in the study by Moet et al [12] use in France were lower than that of the innovator in children, based on a questionnaire completed by their parents [18] . Of the 10 studies on glycopeptide generic products, 3 suggested that some approved generic products may be inferior to the innovator. Rodriguez et al published a case report where a liver transplant recipient with persistent bacteremia after 10 days of intravenous vancomycin generic product had sterile blood cultures 24 hours after a switch to vancomycin innovator [25] . Vesga et al found that, despite similar MICs and MBCs, 3 generic products of vancomycin imported from France, Argentina, and the United States had lower E max than the innovator in the neutropenic mouse thigh S. aureus infection model [5] . The same team subsequently found, using the same model, that serial exposure to generic vancomycin enriches resistant subpopulations, whereas exposure to the innovator reduces resistant subpopulations [6] .
Of the 12 studies published to date on generic products of other antibacterial agent classes, 4 suggested that some approved generic products may be inferior to the innovator. Zuluaga et al found that, despite similar MICs and MBCs, 10 of 20 generic products of gentamicin had lower E max than the innovator in the neutropenic mouse thigh Escherichia coli infection model [31] . Nightingale et al evaluated 65 generic products of clarithromycin from 18 countries and found that 9% did not contain between 95% and 105% of the clarithromycin content claimed in the label, and 19% exceeded the 3% limit for total impurities [33] . Two double-blind studies found that the taste of trimethoprim-sulfamethoxazole generic products was rated lower than that of the innovator [40, 42] .
Regarding study design, almost half of the studies (n = 17) in this systematic review were performed in humans and studied pharmacokinetic parameters (n = 7, mostly bioequivalence studies), clinical efficacy (n = 6), and tolerability or compliance in children (n = 4). Nine studies focused on in vitro efficacy, comparing generic products with the innovator. Six studies were performed in animals, using the neutropenic mouse thigh infection model (n = 5) or the rabbit endocarditis model (n = 1). Five studies investigated the pharmaceutical qualities (purity, content, and potency) of antibacterial generic products. This heterogeneity in the outcomes measured further precluded any meta-analysis, as pooling the studies focusing on major issues (effectiveness in humans), relatively major issues ( potency in vitro or in animal models), and relatively less important-although still significant-issues (taste), would make little sense, and would be of limited clinical relevance.
DISCUSSION
This systematic review of studies that evaluated antibacterial generic products reveals that the data available to date in the literature are limited and heterogeneous. This precludes any attempt to generalize their findings. Indeed, even for the classes of antibacterial agents that received the most attention (ie, β-lactams and glycopeptides), published studies have not consistently demonstrated that some generic products approved for use in humans were inferior to the innovator. The level of evidence from the 6 clinical studies that evaluated the efficacy of antibacterial generic products was low. One case report and 1 quasi-experimental study suggested that generic products of, respectively, vancomycin and cefuroxime, were less potent than the innovator, whereas 3 retrospective cohort studies that enrolled a total of 1597 patients treated with meropenem or imipenem/cilastatin found no significant difference between the generic products and the innovator in terms of clinical outcome.
One randomized, open-label, clinical trial found that a generic product of clarithromycin did not significantly differ from the innovator in terms of clinical or bacteriological efficacy or in terms of tolerability. In summary, none of the clinical studies that compared the efficacy of generics and innovators in humans is sufficient to raise significant concern on the efficacy of generics, as only 1 isolated case report and 1 quasi-experimental study suggested that generics may be suboptimal. Of note, the 4 studies that are often cited to document the suboptimal efficacy of generic products as compared to the innovator [5, 6, 8, 31] were all performed in an animal model that has not been validated for the evaluation of the efficacy of antibacterial agents, that is, the neutropenic mouse thigh infection model. Only 1 study evaluated the efficacy of generic products in an animal model with long track records for the evaluation of the bactericidal effect of antibacterial agents, that is, the rabbit endocarditis model [30] . The latter study evaluated 6 vancomycin generic products approved for use in the United States and Europe, and did not confirm the results observed in the neutropenic mouse thigh infection model [5] . Discrepancies between animal models are not rare, and may be responsible for erroneous assumptions, as was the case with initial studies on the role of Panton-Valentine leukocidin in the pathogenesis of community-associated methicillin-resistant S. aureus (MRSA) [43] . Hence, further studies with the appropriate animal model(s) would be required to judge the comparative in vivo efficacy of generic products and the innovator. Given that most in vitro studies (11/14 [78.6%]) found no significant difference between the generic products and the innovator in terms of MICs and MBCs, we would expect similar in vivo efficacy in an animal model with impaired immunity, such as the neutropenic mouse. Some authors suggested that discrepancies between in vitro and in vivo efficacy could be related to excess impurities, a significant issue with antibacterial agents such as vancomycin [5] . However, this hypothesis has not been confirmed by 2 recent studies where the quality parameters of all parenteral vancomycin products tested surpassed the US Pharmacopeia acceptance criteria, including for generic products that were suboptimal in the neutropenic mouse model [28, 29] . Last, the finding by Rodriguez et al that serial exposure to generic vancomycin enriches resistant subpopulations, whereas exposure to the innovator reduces resistant subpopulations, remains unexplained [6] . It must be outlined that this intriguing phenomenon was observed in the neutropenic mouse thigh infection model after 12 sets of experiments in the model (ie, isolates recovered from an experiment were reinoculated to new groups of animals, and this process was repeated 12 times). Given the complexity of this study design, the results may not be relevant to the clinical use of vancomycin in humans. In addition, these findings have not been confirmed in the rabbit model of MRSA endocarditis [44] . The current controversy on the equivalence of generic medicinal products is of paramount importance, as their volume surpasses that of branded medicinal products, and is continuously increasing, accounting for two-thirds of the worldwide consumption of antimicrobial agents in 2010 (source: IMS Health [2] ). Promotion of the use of generic products has the objective to decrease healthcare costs without compromising quality of care and patient safety. Hence, to be approved for use in humans, antibacterial generic products must comply with standards of quality, efficacy, and reliability, as dictated by regulatory authorities and international organizations (eg, FDA, EMA, and WHO). Although in some countries the quality of available medicinal products may be inadequate in terms of content of active ingredient, this issue also applies to branded drugs, as most of these substandard drugs are counterfeit products [45] . These sobering facts are out of the scope of this systematic review on antibacterial generic products that received regulatory approval. Among other concerns raised by the expanded access to generic products, Jensen et al found a relationship between community consumption and the number of trade names of oral ciprofloxacin. In their study, the introduction of generic ciprofloxacin in Denmark was followed by a sharp increase in the total consumption of ciprofloxacin (from 0.13 to 0.33 defined daily doses/1000 inhabitant-days), while the frequency of ciprofloxacin resistance increased by 200% [32] . This study and others are reminders that drug policies supporting the use of antibacterial generic products must ensure that the reduced price of antibacterial treatments does not translate to increased use [46, 47] . Otherwise, excess use of antibiotics and its ecological impact on bacterial resistance would invariably reduce the economical benefit brought by the use of generics.
This systematic review on the efficacy and quality of antibacterial generic products approved for use in humans has limitations. First, as in most literature reviews, our findings are sensitive to publication bias, implying that the studies analyzed may not be representative of all the studies performed on this topic. Indeed, "positive" studies (ie, studies that found a significant difference between generic products and the innovator), are probably more likely to be submitted for publication and more likely to be accepted by editors. In this regard, our finding that 37.8% of studies reported significant differences between generic products and the innovator is probably an overestimate. Second, the economical consequences of drug policies for increased use of generic products may also carry a risk of bias, in 2 opposite directions. Whereas pharmaceutical companies who own an innovator product would probably encourage the publication of studies suggesting that generic products are suboptimal, regulatory authorities and international organizations would try their best to demonstrate that this is not the case. Last, most of these studies were not adequately powered to demonstrate noninferiority. Hence, the absence of any significant difference in the parameters evaluated cannot be interpreted as evidence that the generics are equivalent to the innovators. Despite these limitations, our systematic review provides a global picture of all studies published to date. Their limited number and their heterogeneity did not allow for a meta-analysis. Indeed, studies comparing the effectiveness of generics and innovators in humans could obviously not be pooled with studies comparing taste and acceptability of oral solutions in children, or with studies comparing potencies in vitro and in animal models. However, we found no convincing data that antibacterial generic products approved by regulatory authorities would be suboptimal compared with the innovator. This suggests that additional evidence would be needed before considering a revision of the marketing authorization process for injectable and oral antibacterial generic products.
Notes
